Assertio (ASRT)
(Real Time Quote from BATS)
$1.07 USD
+0.05 (4.90%)
Updated May 17, 2024 03:49 PM ET
3-Hold of 5 3
C Value B Growth D Momentum B VGM
Brokerage Reports
Assertio Holdings, Inc. [ASRT]
Reports for Purchase
Showing records 41 - 60 ( 115 total )
Company: Assertio Holdings, Inc.
Industry: Medical - Drugs
Raise Target To $8 On Higher EPS Forecast And Shift To 2024 Valuation.
Provider: Sidoti CSR
Analyst: Research Department
Company: Assertio Holdings, Inc.
Industry: Medical - Drugs
Company: Assertio Holdings, Inc.
Industry: Medical - Drugs
3Q:22 Results Solid As ASRT Benefits From Strong Product Line Advance And Greater Operating Efficiencies
Provider: Sidoti CSR
Analyst: Research Department
Company: Assertio Holdings, Inc.
Industry: Medical - Drugs
Company: Assertio Holdings, Inc.
Industry: Medical - Drugs
Company: Assertio Holdings, Inc.
Industry: Medical - Drugs
Company: Assertio Holdings, Inc.
Industry: Medical - Drugs
Sympazan Acquistion Could Drive Valuation Expansion
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: Assertio Holdings, Inc.
Industry: Medical - Drugs
Expect Better 3Q:22 Results Year-Over-Year As ASRT Benefits From Improved Top Line
Provider: Sidoti CSR
Analyst: Research Department
Company: Assertio Holdings, Inc.
Industry: Medical - Drugs
Our Inaugural Healthcare Opportunities Conference in New York City on October 6th
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Assertio Holdings, Inc.
Industry: Medical - Drugs
Our Inaugural Healthcare Opportunities Conference in New York City on October 6th
Provider: Roth Capital Partners, Inc.
Analyst: PIROS E
Company: Assertio Holdings, Inc.
Industry: Medical - Drugs
Company: Assertio Holdings, Inc.
Industry: Medical - Drugs
Company: Assertio Holdings, Inc.
Industry: Medical - Drugs
Contend Stock Pullback Overdone Following Proposed Convertible Notes Offering That Addresses Debt Maturity And Provides Increased Cash Liquidity
Provider: Sidoti CSR
Analyst: Research Department
Company: Assertio Holdings, Inc.
Industry: Medical - Drugs
2Q22 Recap - Indocin Near-Term Driver; M&A Long-Term
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: Assertio Holdings, Inc.
Industry: Medical - Drugs
2Q:22 Results Solid As ASRT Benefits From Strong Line Advance And Greater Operating Efficiencies
Provider: SIDOTI CSR
Analyst: Research Department
Company: Assertio Holdings, Inc.
Industry: Medical - Drugs
Company: Assertio Holdings, Inc.
Industry: Medical - Drugs
Company: Assertio Holdings, Inc.
Industry: Medical - Drugs
Company: Assertio Holdings, Inc.
Industry: Medical - Drugs
Expect Better 2Q:22 Results Year-Over-Year As ASRT Benefits From Improved Top Line
Provider: SIDOTI CSR
Analyst: Research Department
Company: Assertio Holdings, Inc.
Industry: Medical - Drugs
Initiate Coverage Of Assertio Holdings, Inc. With a $6 Price Target And Moderately Risky Rating
Provider: SIDOTI CSR
Analyst: Research Department